ArticleAging2022
Second primary malignancies in cervical cancer and endometrial cancer survivors: a population-based analysis.
Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Second primary cancers among females with a first primary cervical, uterine and ovarian cancer: a population-based study in North Portugal.Cancer causes & control : CCC · 2026Article
- The risk of radiation-associated second cancer in patients with cervical cancer following radiotherapy from 1975 to 2019.The oncologist · 2025Article
- Chronic myelogenous leukemia secondary to colon cancer: A case report.World journal of gastrointestinal oncology · 2025Article
- Association between radiation therapy for primary endometrial cancer and risk of second primary malignancies: a retrospective cohort study.Scientific reports · 2024Article
- The contribution of second primary cancers to the mortality of patients with a first primary breast cancer.Breast cancer research and treatment · 2024Article
- Treatment of secondary uterine malignancy following radiotherapy for cervical cancer: a study based on the SEER database.BMC women's health · 2024Article
- High-grade serous papillary ovarian carcinoma combined with nonkeratinizing squamous cell carcinoma of the cervix: a case report.Frontiers in oncology · 2024Article
- Nomograms constructed for predicting diagnosis and prognosis in cervical cancer patients with second primary malignancies: a SEER database analysis.Journal of cancer research and clinical oncology · 2023Article
- Synchronous gastric cancer complicated with chronic myeloid leukemia (multiple primary cancers): A case report.World journal of clinical cases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe evaluated the relative attribution and interactions of treatment and patient-related risk factors for second primary malignancies (SPMs) in cervical and endometrial cancer survivors.
methodsStage I-III cervical and endometrial cancer survivors' data from the Surveillance, Epidemiology, and End Results (SEER) registry between January 1988 and December 2015 were analyzed. The standardized incidence ratio (SIR), excess absolute risk (EAR), and corresponding 95% confidence interval (95% CI) values were calculated. Analyses were classified based on proxies of human papillomavirus (HPV), smoking, hormone, and radiotherapy (RT) status. Additive and multiplicative interactions were assessed.
resultsCervical cancer survivors had a higher risk for developing potentially HPV and smoking-related SPMs, especially in the RT group (SIR
conclusionsRT, HPV, and smoking promote SPMs in cervical cancer to different extents. The SPM burden in cervical cancer survivors could be mostly attributed to smoking and RT and their interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.